Episode 126: AML Series, Pt 12 - Treatment of patients with relapsed/refractory disease episode artwork

EPISODE · Jan 8, 2025

Episode 126: AML Series, Pt 12 - Treatment of patients with relapsed/refractory disease

from The Fellow on Call: The Heme/Onc Podcast · host TheFellowOnCall HemeOncPodcast

This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on our discussions week-to-week. An exciting treatment paradigm that is ever-evolving! Episode contents: - How do we define primary induction failure in AML? - What are options for treatment of refractory disease? What is the mechanism of action of these treatment options? - What are options for relapsed disease? - What targeted therapies are available for relapsed AML? ****This episode is sponsored by our global research partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on our discussions week-to-week. An exciting treatment paradigm that is ever-evolving! Episode contents: - How do we define primary induction failure in AML? - What are options for treatment of refractory disease? What is the mechanism of action of these treatment options? - What are options for relapsed disease? - What targeted therapies are available for relapsed AML? ****This episode is sponsored by our global research partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast

NOW PLAYING

Episode 126: AML Series, Pt 12 - Treatment of patients with relapsed/refractory disease

0:00 0:00

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Fellow on Call: The Heme/Onc Podcast?

Episode duration information is not available.

When was this The Fellow on Call: The Heme/Onc Podcast episode published?

This episode was published on January 8, 2025.

What is this episode about?

This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on...

Can I download this The Fellow on Call: The Heme/Onc Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!